Los Angeles Capital Management’s Sana Biotechnology SANA Stock Holding History

Los Angeles Capital Management’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$216K	Buy	74,827 +73,333	+4,909%	+$289K	﹤0.01%	1121
2025 Q4	$7.32K	Sell	1,494 -21,716	-94%	-$97.2K	﹤0.01%	2189
2025 Q3	$82.4K	Sell	23,210 -45	-0.2%	-$163	﹤0.01%	1323
2025 Q2	$63.5K	Buy	+23,255	New	+$48K	﹤0.01%	1286
2024 Q2	–	Sell	-70,245	Closed	-$702K	–	1270
2024 Q1	$702K	Sell	70,245 -64,393	-48%	-$482K	﹤0.01%	789
2023 Q4	$549K	Sell	134,638 -1,043	-0.8%	-$3.84K	﹤0.01%	839
2023 Q3	$525K	Buy	135,681 +1,043	+0.8%	+$5.61K	﹤0.01%	813
2023 Q2	$802K	Sell	134,638 -3,700	-3%	-$21.3K	﹤0.01%	707
2023 Q1	$452K	Sell	138,338 -2,981	-2%	-$11.9K	﹤0.01%	886
2022 Q4	$558K	Hold	141,319	–	–	﹤0.01%	862
2022 Q3	$848K	Sell	141,319 -16,170	-10%	-$117K	﹤0.01%	757
2022 Q2	$1.01M	Sell	157,489 -147,177	-48%	-$938K	0.01%	720
2022 Q1	$2.52M	Buy	+304,666	New	+$2.46M	0.01%	476

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

IHAM

Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Los Angeles Capital Management's SANA Position: Q1 2026 in Review

Los Angeles Capital Management increased its Sana Biotechnology (SANA) stake by 4,909% in Q1 2026, buying an estimated $289K and bringing the position to 74,827 shares worth $216K. The position accounts for ﹤0.01% of the portfolio, ranked #1121.

Los Angeles Capital Management first reported a position in SANA in Q1 2022 and has held it in 13 quarters since. The position peaked at $2.52M in Q1 2022. 202 funds tracked by Wall St. Rank hold SANA as of Q1 2026.

Los Angeles Capital Management held 74,827 shares of Sana Biotechnology worth $216K as of Q1 2026.
Los Angeles Capital Management bought 73,333 Sana Biotechnology shares in Q1 2026, an estimated $289K.
Sana Biotechnology made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1121 holding.
Los Angeles Capital Management first reported a position in Sana Biotechnology in Q1 2022 and has held it in 13 quarters since.
Los Angeles Capital Management's Sana Biotechnology position peaked at $2.52M in Q1 2022.
202 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.